Navigation Links
Amgen to Present at the Leerink Swann Global Healthcare Conference
Date:2/14/2012

THOUSAND OAKS, Calif., Feb. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time  on Thursday, Feb. 16, 2012, at the Waldorf Astoria Hotel in New York City.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 

 

 

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen to Acquire Micromet
2. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
3. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen Announces 2012 First Quarter Dividend
6. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
7. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
8. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
9. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
10. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
11. Amgen Announces 2011 Fourth Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2014)... Australia , July 17, 2014  Prana Biotechnology ... provided an update on its clinical development program for ... the Florey Institute of Neuroscience and Mental Health, The ... Phase 2 IMAGINE and EURO trials in his presentation ... Copenhagen, Denmark . The presentation is ...
(Date:7/17/2014)... only work with a certain incident polarization direction. In ... polarization direction of linearly polarized light. A common polarizer ... a birefringent material (such as quartz or mica). The ... of the crystal, the wavelength of light. Considering the ... integrate on circuits. Then what kind of polarizer can ...
(Date:7/17/2014)...  Exelixis, Inc. (Nasdaq: EXEL ) is ... treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use ... a partnership with Roche to commercialize, market and distribute ... treatment of melanoma by late 2015, after positive phase-three ... distributed in the U.S. by EXEL, and in ...
(Date:7/17/2014)... LOS ANGELES , July 17, 2014 /PRNewswire-USNewswire/ ... of genetic switches in plants, setting the stage ... how plants adapt to environmental changes and to ... The collection, which took more than ... about 2,000 clones of plant transcription factors, nature,s ...
Breaking Biology Technology:Prana Alzheimer's disease Development Program update 2Prana Alzheimer's disease Development Program update 3Prana Alzheimer's disease Development Program update 4Prana Alzheimer's disease Development Program update 5Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 2First Comprehensive Library of Master Genetic Switches in Plants 2First Comprehensive Library of Master Genetic Switches in Plants 3First Comprehensive Library of Master Genetic Switches in Plants 4
... www.mchange.org Milwaukee As the highway reconstruction ... leveled at the amount of money, $685,000, spent on a ... , ,The Web site for the Marquette Interchange Project ... a joint venture between the consultants working on the interchange, ...
... sell advertising to competitors of Geico Corp. who use ... court in Virginia has ruled. Advertising based on Web ... Googles business. In the third quarter, about half of ... also called sponsored links. , ,This case involved ...
... companies out there will give you a logo at no cost, ... free Web site. I guess the nextbig thing will be that ... and how are they doing this? , ,The Internet has removed ... issues in real time without the fancy decorum and the big-time ...
Cached Biology Technology:$685,000 too much for construction Web site, critics say 2$685,000 too much for construction Web site, critics say 3Google wins first battle in trademark war 2Free branding? Why not? 2Free branding? Why not? 3
(Date:7/21/2014)... by neurobiologist Luke Remage-Healey at the University of ... the brains of young birds enhance their ability ... development. This period has a parallel to universal ... separate study, the UMass Amherst neuroscientist and colleagues ... the brain,s auditory cortex enhances the representation of ...
(Date:7/21/2014)... runoff is causing problems for the world,s water ... Agency found stormwater runoff to be one of ... rivers, streams, lakes, ponds, reservoirs, bays, and estuaries. ... fish and wildlife populations, foul drinking water, and ... Carolina State University are looking to rain gardens ...
(Date:7/21/2014)... Cystoid macular edema (CME) is a common complication ... in which patients typically lose night and side vision ... also decrease central vision. Current treatments for CME in ... adverse results. , Researchers from the Massachusetts Eye and ... Medicine tested whether the extent of retinal swelling due ...
Breaking Biology News(10 mins):Studying estrogens made by the brain may offer new insights in learning and memory 2Studying estrogens made by the brain may offer new insights in learning and memory 3Filter bed substrates, plant types recommended for rain gardens 2Iodine may alleviate swelling in retinitis pigmentosa patients' retinas 2
... have much in common with a Rottweiler, you might be ... a cave in the Altai Mountains of Siberia for 33,000 ... domestication and, together with equally ancient dog remains from a ... occurred repeatedly in different geographic locations rather than with a ...
... is available in German . Mate ... animal species. During mating season male testosterone levels rise, ... features. Male bonobos, however, invest much more into friendly ... collide with this increased tendency towards forming pair-relationships. ...
... 26 million Americans with diabetes, drawing blood is the ... invasive and at least minimally painful. Researchers at Brown ... check blood sugar levels by measuring glucose concentrations in ... convergence of nanotechnology and surface plasmonics, which explores the ...
Cached Biology News:Dog skull dates back 33,000 years 2Dog skull dates back 33,000 years 3Bonobos' unusual success story 2Biochip measures glucose in saliva, not blood 2Biochip measures glucose in saliva, not blood 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: